MK-7 vs MK-4 for NZ Buyers: 360 mcg MK-7 Slowed Coronary Calcification

For most people taking vitamin K2 for daily bone and cardiovascular maintenance, MK-7 is the more practical choice. It has a longer half-life, stays detectable in serum far longer than MK-4, and the strongest recent trial evidence uses microgram-level MK-7 doses. MK-4 shows effects mainly at high, pharmacological doses studied under clinical supervision. Anyone on blood thinners should talk to a prescriber before changing K2 intake in any form.

TL;DR:

• Daily routine use favors MK-7 because it remains detectable in serum for up to 48 hours, allowing a single microgram dose to maintain steady vitamin K activity.
• High-dose MK-4 protocols used in clinical trials involve milligram amounts that are typically above over-the-counter supplement levels and require medical supervision.
• The two forms differ greatly in half-life, serum detectability, and dosing, so they are not interchangeable despite both being labeled as vitamin K2.
• The two-year VitaK-CAC study showed that 360 micrograms of MK-7 daily can significantly slow coronary artery calcification progression in patients with existing cardiovascular disease.
• People on blood thinners like warfarin must consult a healthcare professional before altering K2 intake, because vitamin K impacts INR and bleeding risk.

Table of Contents

• How MK-7 and MK-4 behave in the body and why dosing differs
• Clinical evidence for bone outcomes: what meta-analyses and trials show
• Cardiovascular evidence: trials addressing arterial or coronary calcification
• Safety, contraindications, and how to manage interactions
• A practical checklist for choosing between MK-7 and MK-4
• Why this guide leans on trial data over trends
• Finding a K2 supplement worth trusting
• Sources
• FAQ

How MK-7 and MK-4 behave in the body and why dosing differs

The practical gap between these two forms starts with pharmacokinetics, not marketing. A pharmacokinetic study comparing menaquinone-4 and menaquinone-7 bioavailability in healthy women found that MK-7 reaches peak serum concentration around six hours after dosing and remains measurable for up to 48 hours. MK-4 given at nutritional doses often failed to raise detectable serum levels at all in the same study.

MK-7 stays measurable in blood for an extended period after a single dose, while MK-4 at nutritional doses often cannot be detected in serum at all, according to the Nutrition Journal comparison. That difference in persistence is the main reason supplement formulators and trial designers lean toward MK-7 for once-daily products meant to maintain steady vitamin K activity.

Dosing conventions reflect this split:

• MK-7 supplements typically use microgram doses, often in the range tested in cardiovascular trials.
• MK-4 trial protocols have historically used much larger doses, sometimes in the tens of milligrams per day, to drive measurable changes in bone biomarkers.
• A microgram dose of MK-7 and a milligram dose of MK-4 are not interchangeable: the numbers look small for MK-7 and large for MK-4, but they are not directly comparable because the two forms clear the body at very different rates.

The practical consequence shows up in adherence and formulation. Because MK-7 persists longer in circulation, a single daily capsule can maintain steadier vitamin K-dependent protein activation. MK-4 protocols that rely on high pharmacological doses are generally designed and monitored by a clinician rather than taken as an open-ended over-the-counter routine, because the doses involved sit well above what a typical multivitamin or bone-support product contains. This is part of why label comparisons between “K2 MK-4” and “K2 MK-7” products can be misleading if the reader does not notice the unit difference between micrograms and milligrams.

Clinical evidence for bone outcomes: what meta-analyses and trials show

The clearest evidence for vitamin K2 and bone health comes from pooled trial data rather than any single study. A systematic review and meta-analysis of randomized controlled trials covering postmenopausal osteoporosis combined 16 trials and 6,425 subjects. It found that vitamin K2 supplementation improved lumbar spine bone mineral density and reduced undercarboxylated osteocalcin, a marker of inactive, poorly carboxylated bone protein. A sensitivity analysis within that same review found a fracture risk reduction with a relative risk of 0.43.

A separate meta-analysis combining vitamin K and calcium trials found a modest but statistically significant gain in lumbar spine bone mineral density, with a standardized mean difference of 0.20, alongside a consistent drop in undercarboxylated osteocalcin.

Pooled trial data show vitamin K2 supplementation improving lumbar spine bone density and lowering undercarboxylated osteocalcin, with a sensitivity analysis showing a fracture risk reduction (RR = 0.43) across 16 randomized controlled trials. Systematic review and meta-analysis, PubMed

A few distinctions matter when reading this evidence:

• Many of the bone trials that produced strong osteocalcin results used MK-4 at pharmacological doses notably higher than what a standard over-the-counter MK-4 supplement contains.
• Other bone trials used longer-term MK-7 supplementation at microgram doses to maintain steady carboxylation activity rather than to force a large short-term biomarker shift.
• Bone mineral density changes in these trials are gradual: meaningful shifts typically require sustained supplementation over months to years, not weeks.

For someone without osteoporosis looking for general bone support, the realistic expectation is a modest contribution to bone mineralization over time, paired with calcium, vitamin D, protein, and weight-bearing exercise, rather than a stand-alone fix. For someone managing diagnosed osteoporosis, the high-dose MK-4 protocols used in some trials are a clinical decision, not a self-directed supplement choice, given the dose gap between study protocols and typical retail products.

Cardiovascular evidence: trials addressing arterial or coronary calcification

The most direct cardiovascular evidence for K2 comes from a two-year randomized trial, the VitaK-CAC study, published in JAMA Cardiology. It tested 360 micrograms of MK-7 per day in patients with symptomatic coronary artery disease and measured coronary artery calcification progression using imaging over two years.

A two-year randomized trial found that a daily dose of MK-7 significantly slowed coronary artery calcification progression compared with placebo, with statistical significance, according to the JAMA Cardiology trial. Reporting on the trial noted that MK-7 plasma levels rose meaningfully in the treatment group, and that baseline markers of vitamin K status may help predict who responds best.

A few caveats apply before extending this result broadly:

• The trial enrolled patients who already had symptomatic coronary artery disease, not a general healthy population, so the findings do not automatically generalize to everyone.
• Coronary artery calcification is a surrogate imaging marker, not a direct measure of heart attacks or mortality, so slower calcification progression is a meaningful but intermediate signal rather than a confirmed clinical outcome.
• Researchers have pointed to potential synergy with vitamin D status and noted that larger trials in broader populations are still needed before firm population-wide recommendations can be made.

For readers without diagnosed cardiovascular disease, this trial is best read as a reason MK-7 is taken seriously in cardiovascular research, not as a guarantee of the same result outside a similar patient profile.

Safety, contraindications, and how to manage interactions

The single most important safety issue with any form of vitamin K2 involves anticoagulant medications, particularly warfarin. Vitamin K works against warfarin’s mechanism, so any meaningful change in K2 intake, whether starting, stopping, or switching doses, can shift INR readings and reduce or increase bleeding risk. This applies to MK-4 and MK-7 alike.

Trial data on MK-7, including the two-year coronary calcification study, generally describe the supplement as well tolerated at the doses used. Evidence specific to pregnancy and breastfeeding is limited, so those groups should treat K2 supplementation as a conversation with a healthcare provider rather than a default addition.

Practical steps for anyone starting or adjusting K2, especially at higher risk:

1. Write down your current medications and typical dietary vitamin K intake before changing anything.
2. If you take warfarin or another anticoagulant, talk to your prescriber before starting, stopping, or changing your K2 dose.
3. Introduce one change at a time rather than adjusting K2, D3, and calcium all at once, so any effect is easier to trace.
4. Ask about follow-up INR testing if you are on anticoagulants and plan to start K2.

Pro Tip: If you are on any blood-thinning medication, bring your supplement bottle, not just the name, to your next appointment so your prescriber can check the exact dose and form.

A practical checklist for choosing between MK-7 and MK-4

For routine, once-daily maintenance, MK-7 is the more practical pick given its longer half-life and the microgram doses used in recent trials. MK-4 is better reserved for clinician-directed, high-dose protocols rather than casual daily use, since the doses that show measurable effects in trials are well above typical retail products.

When comparing labels, a few features are worth checking:

• Dose unit: confirm whether the label lists micrograms (typical for MK-7) or milligrams (typical for MK-4), since mixing these up leads to very different intake levels.
• Source: natto-derived MK-7 and synthetic MK-7 are both used in supplements; either can work, but the label should state which.
• Formulation: an oil-based softgel generally supports absorption better than a dry tablet, since vitamin K2 is fat-soluble.
• Testing: look for a certificate of analysis or third-party testing disclosure, particularly for sport or performance-focused products.
• Combination: some products pair K2 with vitamin D3, which is worth considering given how often the two nutrients are discussed together for bone health.

Nutrient pairing matters as much as the K2 form itself. Vitamin D status affects how the body uses calcium, and vitamin D dosing is worth reviewing alongside any K2 plan, along with adequate calcium, protein, magnesium, and regular weight-bearing exercise.

Why this guide leans on trial data over trends

This guide draws on randomized controlled trials, systematic reviews, and pharmacokinetic studies published in peer-reviewed journals, including the two-year MK-7 coronary calcification trial and meta-analyses of K2 and bone outcomes. The goal was to separate what the strongest evidence supports from what supplement marketing often implies.

The evidence has real limits. Several trials involve specific populations, such as people with existing coronary artery disease or postmenopausal women, and the results do not automatically apply to every reader. Anyone with a diagnosed bone or cardiovascular condition, or anyone on anticoagulant medication, should treat this article as background information and bring specific questions to a clinician familiar with their history.

— Blake

Finding a K2 supplement worth trusting

Some retailers stock products with transparent ingredient listings so you can check the dose and form before purchase.

If you are comparing K2 options, the Health & Wellness category is a reasonable place to start browsing, and products like the GAT Sport Essential D3 + K2 Bone Support formula show what a combined D3 and K2 label should disclose: dose, form, and ingredient source.

• Check the dose unit on any K2 label before comparing products.
• Look for a combined D3 and K2 formulation if you want both nutrients in one capsule.
• Reach out to customer service if a label’s sourcing or dose is unclear.

Browse the full category range to compare formulations side by side before you check out.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

Vitamin K2 is not one molecule. It is a family of compounds called menaquinones, labeled MK-4 through MK-13 based on the length of a side chain attached to the core structure. That side chain length changes how the body absorbs, transports, and clears each form, which is why MK-4 and MK-7 behave so differently despite sharing the same vitamin K2 label.

MK-4 is the form found in animal foods: egg yolks, chicken, and organ meats like liver carry small amounts. The body also converts some dietary vitamin K1 into MK-4 through a tissue-level pathway, though this conversion is limited and does not reliably raise blood levels the way supplementation can. MK-7, in contrast, comes largely from fermented foods, most notably natto (a fermented soybean dish common in Japanese cuisine) and certain fermented cheeses, where bacterial fermentation produces the longer side chain.

Common dietary and supplement sources include:

• Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials
• Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial | JAMA Cardiology
• Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women | Nutrition Journal

The body can convert some forms of vitamin K into MK-4 in peripheral tissue, but this is a separate process from absorbing preformed MK-4 or MK-7 from food or a capsule, and the two forms do not reach the bloodstream in comparable amounts at matched doses.

FAQ

Which is better, vitamin K2 MK-4 or MK-7?

For routine daily maintenance, MK-7 is generally preferred because it has a longer half-life and stays detectable in serum far longer than MK-4 at nutritional doses, as shown in pharmacokinetic research. MK-4 shows effects mainly at high, pharmacological doses used in clinician-directed trials.

Which vitamin K2 is better for osteoporosis, MK-4 or MK-7?

Evidence for osteoporosis includes both forms: a large meta-analysis of 16 randomized trials found improved bone density and a fracture risk reduction (RR = 0.43 after sensitivity analysis), with some trials using high-dose MK-4 and others using longer-term MK-7. Anyone with diagnosed osteoporosis should discuss form and dose with a clinician rather than choosing based on a label alone.

Who should avoid taking K2-MK7?

People on anticoagulant medications like warfarin need medical guidance before starting MK-7, since any change in vitamin K intake can affect INR and bleeding risk. Evidence in pregnancy and breastfeeding is also limited, so those groups should check with a healthcare provider first.

Which vitamin K2 supplement is better, MK-4 or MK-7 with D3?

A combined MK-7 and D3 formulation is a reasonable default for most people seeking daily bone support, since MK-7’s longer half-life pairs well with D3’s role in calcium regulation. MK-4 combinations are more often used in clinician-directed, higher-dose protocols rather than routine daily products.

Recommended

• Vitamin K2 with D3: Do You Need Both for Bone Health?